What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?
Journal of Surgical Research · 2024
DOI: 10.1016/j.jss.2024.04.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2024. Verfasst von Emily Forester und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Rowan-Virtua School of Os…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, BRCA1 Protein, BRCA2 Protein, Molecular Targeted Therapy. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: DESTINY B04 provided clinical meaning to a new classification of human epidermal growth factor 2 (HER2) expression in breast cancer: HER2-low. Patients with germline breast cancer type 1 gene pathogenic variants (gBRCA1) often develop triple negative breast cancer (TNBC), but the proportion who could be classified as HER2-low and qualify for an additional targeted therapy option is unknown. This study aims to characterize the proportion of gBRCA1 or germline breast cancer type 2 gene pathogenic variants patients for whom these novel targeted therapies may be an option. METHODS: We performed a retrospective chart review of patients with gBRCA1/2 treated at our institution for invasive breast cancer from 2000 to 2021. Synchronous or metachronous contralateral breast cancers were recorded separately. HER2 status was determined by immunohistochemistry and fluorescence in situ hybridization. We excluded patients without complete HER2 data. RESULTS: Among the 95 breast cancers identified in our cohort of 85 gBRCA1/2 patients, 41 (43%) were TNBC, 38 (40%) were hormone receptor positive (HR+)/HER2-negative, and 16 (17%) were HER2-positive based on standard conventions. We found that 82% of the HR+/HER2-cancers and 66% of TNBCs would be reclassified as HER2-low. After stratifying by BRCA gene status, 64% of cancers in patients with gBRCA1 and 58% of cancers in patients with germline breast cancer type 2 gene pathogenic variants were HER2-low. CONCLUSIONS: A significant portion of gBRCA1/2 patients who were previously diagnosed with TNBC or HR+/HER2- breast cancer would now be classified as HER2-low and could be considered for the use of trastuzumab deruxtecan in the metastatic setting. Outcome differences from therapy changes in this cohort should now be assessed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey.
- Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
- Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- Department of Medical Oncology, MedStar Health, Washington, District of Columbia.
- Hackensack Meridian Health Network, Edison, New Jersey.
- Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Zitieren
APA
Forester, E., Belsare, A., Kim, D. W., Whitaker, K., Obeid, E., Goldstein, L. J., Bleicher, R. J., Daly, M. B., & Williams, A. D. (2024). What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2024.04.032
Vancouver
Forester E, Belsare A, Kim DW, Whitaker K, Obeid E, Goldstein LJ, et al. What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?. Journal of Surgical Research. 2024. doi:10.1016/j.jss.2024.04.032
BibTeX
@article{Forester2024,
author = {Forester, Emily and Belsare, Aakash and Kim, Dong Won and Whitaker, Kristen and Obeid, Elias and Goldstein, Lori J and Bleicher, Richard J and Daly, Mary B and Williams, Austin D},
title = {What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?},
journal = {Journal of Surgical Research},
year = {2024},
doi = {10.1016/j.jss.2024.04.032}
}
EUVIMED